

7. Literaturverzeichnis

Achtman M., Wall R.A., Bopp M., Kusecek B., Morelli G., Saken E. and Hassan-King M. (1991). Variation in class 5 protein expression by serogroup A meningococci during a meningitis epidemic. *J Infect Dis* **164**, 375-382.

Achtman, M. (1997). Microevolution and epidemic spread of serogroup A *Neisseria meningitidis* – a review. *Gene* **192**, 135-140.

Afanassiev V., Hanemann V. and Wolf S. (2000). Preparation of DNA and protein micro arrays on glass slides coated with an agarose film. *Nucleic Acids Res* **28**, 1-5.

Aho E.L., Dempsey J.A., Hobbs M.M., Klapper D.G. and Cannon J.G. (1991). Characterization of the opa (class5) gene family of *Neisseria meningitidis*. *Mol Microbiol* **5**, 1429-1437.

Angenendt P., Glokler J., Sobek J., Lehrach H. and Cahill D.J. (2003). Next generation of protein microarray support materials: evaluation for protein and antibody microarray applications. *J Chromatogr A* **1009**, 97-104.

Appelmelk B.J., Martin S.L., Monteiro M.A., Clayton C.A., McColm A.A., Zheng P., Verboom T., Maaskant J.J., van den Eijnden D.H., Hokke C.H. *et al.* (1999). Phase variation in *Helicobacter pylori* lipopolysaccharide due to changes in the lengths of poly(C) tracts in alpha3-fucosyltransferase genes. *Infect Immun* **67**, 5361-5366.

Appelmelk B. J., Martino M.C., Veenhof E. Monteiro M.A., Maaskant J.J., Negrini R., Lindh F., Perry M., Del Giudice G. and Vandenbroucke-Grauls C.M. (2000). Phase variation in H type I and Lewis a epitopes of *Helicobacter pylori* lipopolysaccharide. *Infect Immun* **68**, 5928-5932.

Arenkov P., Kukhtin A., Gemmell A., Voloshchuk S., Chupeeva V. and Mirzabekov A. (2000). Protein microchips: use for immunoassay and enzymatic reactions. *Anal Biochem* **278**, 123-131.

Arigita C., van den Berg J., Wensink K., van Steenberg M., Hennink W.E., Crommelin D.J., Kersten G.F. and Jiskoot W. (2004). Immunogenicity of meningococcal PorA formulations encapsulated in biodegradable microspheres. *Eur J Pharm Sci* **21**, 131-141.

Benz R. (1988). Structure and function of porins from gram-negative bacteria. *Annu Rev Microbiol* **42**, 359-393.

Berger U., Sonntag H.G. and Ulbrich C. (1988). Epidemiology of meningococcal infections in the Federal Republic of Germany, 1966-1984. *Zentralbl Bakteriol Mikrobiol Hyg [A]* **268**, 83-102.

- Berrington A.W, Tan Y.C, Srikhanta Y., Kuipers B., van der Ley P., Peak I.R. and Jennings M.P. (2002). Phase variation in meningococcal lipooligosaccharide biosynthesis genes. *FEMS Immunol Med Microbiol* **34**, 267-275.
- Bethell D. and Pollard A.J. (2002). Meningococcal vaccines. *Expert Rev Vaccines* **1**, 75-84.
- Bitter-Suermann D. and Roth J. (1987). Monoclonal antibodies to polysialic acid reveal epitope sharing between invasive pathogenic bacteria, differentiating cells and tumor cells. *Immunol Res* **6**, 225-237.
- Bjune G., Gronnesby J.K., Hoiby E.A., Closs O. and Nokleby H. (1991). Results of an efficacy trail with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. *NIPH Ann.* **14**, 125-130.
- Boslego J., Garcia J., Curz C., Zollinger W., Brandt B., Ruiz S., Martinez M., Arthur J., Underwood P., Silva W., *et al.* (1995). Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. *Vaccine* **13**, 821-829.
- Bradford M.M. (1979). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**, 248-254.
- Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. and Waage A. (1992). Molecular mechanisms in the compartmentalized inflammatory as meningococcal meningitis or septic shock. *Microb Pathog* **13**, 423-431.
- Bussow K., Cahill D., Nietfeld W., Bancroft D., Scherzinger E., Lehrach H. and Walter G. (1998). A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library. *Nucleic Acids Res* **26**, 5007-5008.
- Bussow K., Nordhoff E., Lubbert C., Lehrach H. and Walter G. (2000). A human cDNA library for high-throughput protein expression screening. *Genomics* **65**, 1-8.
- Cahill D.J.(2001). Protein and antibody arrays and their medical applications. *J Immunol Methods* **250**, 81-91.
- Cartwright K., Morris R., Rumke H., Fox A., Borrow R., Begg N., Richmond P. and Poolman J. (1999). Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. *Vaccine* **17**, 2612-2619.
- Catlin, B.W. (1960). Transformation of *Neisseria meningitidis* by deoxyribonucleates from cells and from culture slime. *J Bacteriol* **79**, 579-590.

- Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J., Borsboom D., van der Ark A., van Straaten I., Roholl P., Kuipers B. and Poolman J. (1996). Production, characterization and control of a *Neisseria meningitidis* hexavalent class 1 outer membrane protein containing vesicle vaccine. *Vaccine* **14**, 1001-1008.
- Clark M.D., Panopoulou G.D., Cahill D.J., Bussow K. and Lehrach H. (1999). Construction and analysis of arrayed cDNA libraries. *Methods Enzymol* **303**, 205-233.
- Cohen S., Chang A.C.Y. and Hsu L. (1972). Non chromosomal antibiotic resistance in bacteria: Genetic transformation of *E. coli* by R-factor DNA. *Proc Natl Acad Sci* **69**, 2110-2114.
- Connolly M. and Noah, N. (1999). Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group. *Epidemiol Infect* **122**, 41-49.
- Cooksen S.T., Corrales J.L., Lotero J.O., Ragueira M., Binsztein N., Reeves M.W., Ajello G. and Jarvis W.R. (1998). Disco fever: epidemic meningococcal disease in northeastern Argentina associated with disco patronage. *J Infect Dis* **178**, 266-269.
- Courtney H.S., Hasty D.L. and Dale J.B. (2003). Serum opacity factor (SOF) of *Streptococcus pyogenes* evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci. *Infect Immun* **71**, 5097-5103.
- de Jonge M.I., Bos M.P., Hamstra H.J., Jiskoot W., van Ulsen P., Tommassen J., van Alphen L. and van der Ley P. (2002). Conformational analysis of opacity proteins from *Neisseria meningitidis*. *Eur J Biochem* **269**, 5215-5223.
- de Kleijn E.D., de Groot R., Labadie J., Lafeber A.B., van den Dobbelen G., van Alphen L., van Dijken H., Kuipers B., van Omme G.W., Wala M., Juttman R. and Rumke H.C. (2000). Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. *Vaccine* **14**, 1456-66.
- de Vries F.P., van Der Ende A., van Putten J.P. and Dankert J. (1996). Invasion of primary nasopharyngeal epithelial cells by *Neisseria meningitidis* is controlled by phase variation of multiple surface antigens. *Infect Immun* **64**, 2998-3006.
- de Wildt R.M., Mundy C.R., Gorick B.D. and Tomlinson I.M. (2000). Antibody arrays for high-throughput screening of antibody-antigen interactions. *Nat Biotechnol* **18**, 989-994.
- Dehio C., Gray-Owen S.D. and Meyer T.F. (1998). The role of neisserial Opa proteins with host cells. *Trends Microbiol* **6**, 489-495.
- Edwards M.S. and Baker C.J. (1981). Complications and sequelae of meningococcal infections in children. *J Pediatr* **99**, 540-545.

Epidemiologisches Bulletin, Robert Koch Institut. 16. August 2002 / Nr. 33.

Finne J., Leinonen M. and Makela P.H. (1983). Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. *Lancet* **2**, 355-357.

Fodor S.P., Read J.L., Pirrung M.C., Stryer L., Lu A.T. and Solas D. (1991). Light-directed, spatially addressable parallel chemical synthesis. *Science* **251**, 767-773.

Frasch C.E., van Alphen L., Holst J., Poolman J.T. and Rosenqvist E. (2001). Outer membrane protein vesicle vaccines for meningococcal disease. In: Pollard A.J., Maiden M.C.J., eds Meningococcal vaccines. Totowa, New Jersey: *Humana Press*, 81-107.

Freissler E., Meyer auf der Heyde A., David G., Meyer T.F. and Dehio C. (2000). Syndecan-1 and syndecan-4 can mediate the invasion of OpaHSPG-expressing *Neisseria gonorrhoeae* into epithelial cells. *Cell Microbiol* **2**, 69-82.

Genevrois S., Steeghs L., Roholl P., Letesson J.J. and van der Ley P. (2003). The Omp85 protein of *Neisseria meningitidis* is required for lipid export to the outer membrane. *EMBO J* **22**, 1780-1789.

Gentle I., Gabriel K., Beech P., Waller R. and Lithgow T. (2004). The Omp85 family of proteins is essential for outer membrane biogenesis in mitochondria and bacteria. *J Cell Biol* **164**, 19-24.

Gotschlich E.C., Goldschneider I. and Artenstein M.S. (1969). Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. *J Exp Med* **129**, 1367-1384.

Gram, C. (1884). Über die isolierte Färbung der *Schizomyceten* in Schnitt- und Trockenpräparaten. *Fortschr Med* **2**, 185-189.

Grandi G. (2001). Antibacterial vaccine design using genomics and proteomics. *Trends Biotechnol* **19**, 181-188.

Greenfield S., Sheehe P.R. and Feldman H.A. (1971). Meningococcal carriage in a population of normal families. *J Infect Dis* **123**, 67-73.

Greenwood B. (1999). Manson Lecture. Meningococcal meningitis in Africa. *Trans R Soc Trop Med Hyg* **93**, 341-353.

Grifantini R., Bartolini E., Muzzi A., Draghi M., Frigimelica E., Berger J., Ratti G., Petracca R., Galli G., Agnusdei M. *et al.* (2002). Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. *Nat Biotechnol* **20**, 914-921.

Grifantini R., Bartolini E., Muzzi A., Draghi M., Frigimelica E., Berger J., Randazzo F. and Grandi G. (2002). Gene expression profile in *Neisseria meningitidis* and *Neisseria lactamica* upon host-cell contact: from basic research to vaccine development. *Ann NY Acad Sci* **975**, 202-216.

Haab B.B., Dunham M.J. and Brown P.O. (2001). Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. *Genome Biol*, **2** R4.

Hammerschmidt S., Muller A., Sillmann H., Muhlenhoff M., Borrow R., Fox A., van Putten J., Zollinger W.D., Gerardy-Schahn R. and Frosch M. (1996). Capsule phase variation in *Neisseria meningitidis* serogroup B by slipped-strand mispairing in the polysialyltransferase gene (*siaD*): correlation with bacterial invasion and the outbreak of meningococcal disease. *Mol Microbiol* **20**, 1211-1220.

Hauck C.R. and Meyer T.F. (2003). 'Small' talk: Opa proteins as mediators of *Neisseria*-host-cell communication. *Curr Opin Microbiol* **6**, 43-49.

Hayrinen J., Jennings H., Raff H.V., Rougon G., Hanai N., Gerardy-Schahn R. and Finne J. (1995). Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. *J Infect Dis* **171**, 1481-1490.

Hobbs M.M., Seiler A., Achtman M. and Cannon J.G. (1994). Microevolution within a clonal population of pathogenic bacteria: recombination, gene duplication and horizontal genetic exchange in the *opa* gene family of *Neisseria meningitidis*. *Mol Microbiol* **12**, 171-80.

Hood D.W., Deadman M.E., Jennings M.P., Bisercic M., Fleischmann R.D., Venter J.C. and Moxon E.R. (1996). DNA repeats identify novel virulence genes in *Haemophilus influenzae*. *Proc Natl Acad Sci USA* **93**, 11121-11125.

Houseman B.T., Huh J.H., Kron S.J. and Mrksich M. (2002). Peptide chips for the quantitative evaluation of protein kinase activity. *Nat Biotechnol* **20**, 270-274.

Jennings M.P., Hood D.W., Peak I.R., Virji M. and Moxon E.R. (1995). Molecular analysis of a locus for the biosynthesis and phase-variable expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in *Neisseria meningitidis*. *Mol Microbiol* **18**, 729-740.

Jennings M.P., Virji M., Evans D., Foster V., Srikhanta Y.N., Steeghs L., van der Ley P. and Moxon E.R. (1998). Identification of a novel gene involved in pilin glycosylation in *Neisseria meningitidis*. *Mol Microbiol* **29**, 975-984.

Jennings M.P., Srikhanta Y.N., Moxon E.R., Kramer M., Poolman J.T., Kuipers B. and van der Ley P. (1999). The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in *Neisseria meningitidis*. *Microbiology* **145**, 3013-3021.

- Jódar L., Feavers I.M., Salisbury D. and Granoff D.M. (2002). Development of vaccines against meningococcal disease. *Lancet* **359**, 1499-1508.
- Joos T.O., Schrenk M., Hopfl P., Kroger K., Chowdhury U., Stoll D., Schorner D., Durr M., Herick K., Rupp S., Sohn K. and Hammerle H. (2000). A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. *Electrophoresis* **21**, 2641-2650.
- Josenhans, C., Eaton, K.A., Thevenot T. and Suerbaum, S. (2000). Switching of flagellar motility in *Helicobacter pylori* by reversible length variation of a short homopolymeric sequence repeat in *fliP*, a gene encoding a basal body protein. *Infect Immun* **68**, 4598-4603.
- Kahler C.M. and Stephens D.S. (1998). Genetic basis for biosynthesis, structure and function of meningococcal lipooligosaccharide (endotoxin). *Crit Rev Microbiol* **24**, 281-334.
- Kersten B., Feilner T., Kramer A., Wehrmeyer S., Possling A., Witt I., Zanol M.I., Stracke R., Lueking A., Kreutzberger J., Lehrach H. and Cahill D.J. (2003). Generation of Arabidopsis protein chips for antibody and serum screening. *Plant Mol Biol* **52**, 999-1010.
- Kim T.E., Park S.W., Cho N.Y., Choi S.Y., Yong T.S., Nahm B.H., Lee S. and Noh G. (2002). Quantitative measurement of serum allergen-specific IgE on protein chip. *Exp Mol Med* **31**, 152-158.
- Kleinschmidt J.H. (2003). Membrane protein folding on the example of outer membrane protein A of *Escherichia coli*. *Cell Mol Life Sci* **60**, 1547-1558.
- Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., Torhorst J., Mihatsch M.J., Sauter G. and Kallioniemi O.P. (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat Med* **4**, 844-847.
- Laemmli U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.
- Lander E.S, Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M., FritzHugh W. *et al.* (2001). Initial sequencing and analysis of the human genome. *Nature* **409**, 860-921.
- Lewis L.A., Gipson M., Hartman K., Ownbey T., Vaughn J. and Dyer D.W. (1999). Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of *Neisseria meningitidis* DNM2. *Mol Microbiol* **32**, 977-989.
- Lueking A., Horn M., Eickhoff H., Bussow K., Lehrach H. and Walter G. (1999). Protein microarrays for gene expression and antibody screening. *Anal Biochem* **270**, 103-111.
- Lueking A., Holz C., Gotthold C., Lehrach H. and Cahill D. (2000). A system for dual protein expression in *Pichia pastoris* and *Escherichia coli*. *Protein Expr Purif* **20**, 372-378.

- Lynch E.C., Blake M.S., Gotschlich E.C. and Mauro A. (1984). Studies of porins. Spontaneously transferred from whole cells and reconstituted from purified proteins of *Neisseria gonorrhoeae* and *Neisseria meningitidis*. *Biophys J* **45**, 104-107.
- MacBeath G. and Schreiber S.L. (2000). Printing proteins as microarrays for high-throughput function determination. *Science* **289**, 1760-1763.
- Mandrell R.E., McLaughlin R., Aba Kwaik Y., Lesse A., Yamasaki R., Gibson B., Spinola S.M. and Apicella M.A. (1992). Lipooligosaccharides (LOS) of some *Haemophilus* species mimic human glycosphingolipids and some LOS are sialylated. *Infect Immun* **4**, 1322-1328.
- Manning D.S., Reschke D.K. and Judd R.C. (1998). Omp85 proteins of *Neisseria gonorrhoeae* and *Neisseria meningitidis* are similar to *Haemophilus influenzae* D-15-Ag and *Pasteurella multocida* Oma87. *Microb Pathog* **25**, 11-21.
- Martin P., van de Ven T., Mouchel N., Jeffries A.C., Hood D.W. and Moxon E.R. (2003). Experimentally revised repertoire of putative contingency loci in *Neisseria meningitidis* strain MC58: evidence for a novel mechanism of phase variation. *Mol Microbiol* **50**, 245-257.
- Maskell D., Frankel G. and Dougan G. (1993). Phase and antigenic variation--the impact on strategies for bacterial vaccine design. *Trends Biotechnol* **11**, 506-510.
- Meyer T.F. (1989). [Pathogenic neisseriae--model of bacterial virulence and genetic flexibility] *Immun Infekt* **17**, 113-123.
- Meyer T.F., Gibbs C.P. and Haas R. (1990). Variation and control of protein expression in *Neisseria*. *Annu Rev Microbiol* **44**, 451-477.
- Morse S.A. and Knapp J.S. (1991). The Genus *Neisseria*. In the Prokaryotes. Edited by Balows A., Trüper H.G., Dworhin M., Harder W. and Schleifer K.-H., 2495-2529.
- Moxon E.R., Rainey P.B., Nowak M.A. and Lenski R.E. (1994). Adaptive evolution of highly mutable loci in pathogenic bacteria. *Curr Biol* **4**, 24-33.
- Musacchio A., Carmenate T., Delgado M. and Gonzalez S. (1997). Recombinant Opc meningococcal protein, folded in vitro, elicits bactericidal antibodies after immunization. *Vaccine* **15**, 751-758.
- Naess A., Halstensen A., Nyland H., Pedersen S.H., Moller P., Borgmann R., Larsen J.L. and Haga E. (1994). Sequelae one year after meningococcal disease. *Acta Neurol Scand* **89**, 139-142.

- Newcombe J., Cartwright K., Dyer S. and McFadden J. (1998). Naturally occurring insertional inactivation of the porA gene of *Neisseria meningitidis* by integration of IS1301. *Mol Microbiol* **30**, 453-454.
- Parkhill J., Achtman M., James K.D., Bentley S.D., Churcher C., Klee S.R., Morelli G., Basham D., Brown D., Chillingworth T. *et al.* (2000) Complete DNA sequence of a serogroup A strain of *Neisseria meningitidis* Z2491. *Nature* **404**, 502-506.
- Peck B., Ortkamp M., Diehl K.D., Hundt E. and Knapp B. (1999). Conservation, localization and expression of *HopZ*, a protein involved in adhesion of *Helicobacter pylori*. *Nucleic Acids Res* **27**, 3325-3333.
- Peeters C.C., Rumke H.C., Sundermann L.C., Rouppe van der Voort E.M., Meulenbelt J., Schuller M., Kuipers A.J., van der Ley P. and Poolman J.T. (1996). Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. *Vaccine* **14**, 1009-1015.
- Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., Rosenqvist E., Holst J., Nokleby H., Sotolongo F. *et al.* (1998). Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. *J Infect Dis* **177**, 683-691.
- Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., Jennings G.T., Baldi L., Bartolini E., Capecchi B. *et al.* (2000). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. *Science* **287**, 1816-1820.
- Pollard A.J. and Frasch C. (2001). Development of natural immunity to *Neisseria meningitidis*. *Vaccine* **19**, 1327-1346.
- Poolman J.T. (1995). Development of a meningococcal vaccine. *Infect Agents Dis* **4**, 13-28.
- Rietschel E.T., Kirikae T., Schade F.U., Mamat U., Schmidt G., Loppnow H., Ulmer A.J., Zahringer U., Seydel U., Di Padova F., *et al.* (1994). Bacterial endotoxin: molecular relationships of structure to activity and function. *FASEB J* **8**, 217-225.
- Rietschel E.T., Brade H., Holst O., Brade L., Muller-Loennies S., Mamat U., Zahringer U., Beckmann F., Seydel U., Brandenburg K. *et al.* (1996). Bacterial endotoxin: Chemical constitution, biological recognition, host response and immunological detoxification. *Curr Top Immunol* **216**, 39-81.
- Robinson W.H., DiGennaro C., Hueber W., Haab B.B., Kamachi M., Dean E.J., Fournel S., Fong D., Genovese M.C., de Vegvar H.E. *et al.* (2002). Autoantigen microarrays for multiplex characterization of autoantibody responses. *Nat Med* **8**, 295-301.

- Rosenqvist, E., Hoiby E.A., Wedege E., Brynk K., Kolberg J., Klem A., Ronnila E., Bjune G. and Nokleby H. (1995). Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. *Infect Immun* **63**, 4642- 4652.
- Sachs L. (1992). *Angewandte Statistik*, Springer Verlag, Berlin, Heidelberg. 7. Auflage, Seite 189-193.
- Sambrook J., Fritsch E.F. and Maniatis T. (1989). *Molecular cloning: a laboratory manual* (second edition). Cold Spring Harbor, New York: Cold Spring Harbor Laboratory.
- Sarkari J., Pandit N., Moxon E.R. and Achtman M. (1994). Variable expression of the Opc outer membrane protein in *Neisseria meningitidis* is caused by size variation of a promoter containing poly-cytidine. *Mol Microbiol* **13**, 207-217.
- Saukkonen K., Leinonen M., Abdillahi H. and Poolman J.T. (1989). Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. *Vaccine* **4**, 325-328.
- Saunders N.J., Peden J.F., Hood D.W. and Moxon E.R. (1998). Simple sequence repeats in the *Helicobacter pylori* genome. *Mol Microbiol* **27**, 1091-1098.
- Saunders N.J., Jeffries A.C., Peden J.F., Hood D.W., Tettelin H., Rappuoli R. and Moxon E.R. (2000). Repeat-associated phase variable genes in the complete genome sequence of *Neisseria meningitidis* strain MC58. *Mol Microbiol* **37**, 207-215.
- Schein C.H. (1989). Production of soluble recombinant Proteins in bacteria. *Bio/Technology* **7**, 1141-1148.
- Schlech W.F. 3rd, Ward J.I., Band J.D., Hightower A., Fraser D.W. and Broome C.V. (1985). Bacterial meningitis in the United States, 1978 through 1981. The National Bacterial Meningitis Surveillance Study. *JAMA* **253**, 1749-1754.
- Snyder L.A., Butcher S.A. and Saunders N.J. (2001). Comparative whole-genome analyses reveal over 100 putative phase-variable genes in the pathogenic *Neisseria* spp. *Microbiology* **147**, 2321-2332.
- Song J., Minetti C.A., Blake M.S. and Colombini M. (1998). Successful recovery of the normal electrophysiological properties of PorB (class 3) porin from *Neisseria meningitidis* after expression in *Escherichia coli* and renaturation. *Biochim Biophys Acta* **13**, 289-298.
- Stephens D.S. (1989). Gonococcal and meningococcal pathogenesis as defined by human cell, cell culture and organ culture assays. *Clin Microbiol Rev* **2**, 104-111.
- Stephens R.S. and Lammel C.J. (2001). Chlamydia outer membrane protein discovery using genomics. *Curr Opin Microbiol* **4**, 16-20.

- Stern A., Nickel P., Meyer T.F. and So M. (1984). Opacity determinants of *Neisseria gonorrhoeae*: gene expression and chromosomal linkage to the gonococcal pilus gene. *Cell* **37**, 447-456.
- Stern A., Brown M., Nickel P. and Meyer T.F. (1986). Opacity genes in *Neisseria gonorrhoeae*: control of phase and antigenic variation. *Cell* **47**, 61-71.
- Stern A. and Meyer T.F. (1987). Common mechanism controlling phase and antigenic variation in pathogenic neisseria. *Mol Microbiol* **1**, 5-12.
- Stillman B.A. and Tonkinson J.L. (2000). FAST slides: a novel surface for microarrays. *Biotechniques* **29**, 630-635.
- Sun Y.H., Bakshi S., Chalmers R. and Tang C.M. (2000). Functional genomics of *Neisseria meningitidis* pathogenesis. *Nat Med* **6**, 1269-1273.
- Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., Ketchun K.A., Hood D.W., Peden J.F., Dodson R.J. *et al.* (2000). Complete genome sequence of *Neisseria meningitidis* serogroup B strain MC58. *Science* **287**, 1809-1815.
- Tikhomirov E., Santamaria M. and Esteves K. (1997). Meningococcal disease: public health burden and control. *World Health Stat Q* **50**, 170-177.
- Tinsley C.R. and Heckels J.E. (1986). Variation in the expression of pili and outer membrane protein by *Neisseria meningitidis* during the course of meningococcal infection. *J Gen Microbiol* **132**, 2483-2490.
- Tinsley C.R., Virji M. and Heckels J.E. (1992). Antibodies recognizing a variety of different structural motifs on meningococcal Lip antigen fail to demonstrate bactericidal activity. *J Gen Microbiol* **138**, 2321-2328.
- Tomassen J., Vermeij P., Struyve M., Benz R. and Poolman J.T. (1990). Isolation of *Neisseria meningitidis* mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins. *Infect Immun* **58**, 1355-1359.
- Tsai C.M., Frasch C.E. and Mocca L.F. (1981). Five structural classes of major outer membrane proteins in *Neisseria meningitidis*. *J Bacteriol* **146**, 69-78.
- Unger M.A., Rishi M., Clemmer V.B., Hartman J.L., Keiper E.A., Greshock J.D., Chodosh L.A., Liebman M.N. and Weber B.L. (2001). Characterization of adjacent breast tumors using oligonucleotide microarrays. *Breast Cancer Res* **3**, 336-341.
- van der Ende A., Hopman C.T., Zaat S., Essink B.B., Berkhout B. and Dankert J. (1995). Variable expression of class 1 outer membrane protein in *Neisseria meningitidis* is caused

- by variation in the spacing between the -10 and -35 regions of the promoter. *J Bacteriol* **177**, 2475-2480.
- van der Ende A., Hopman C.T. and Dankert J. (1999). Deletion of *porA* by recombination between clusters of repetitive extragenic palindromic sequences in *Neisseria meningitidis*. *Infect Immun* **67**, 2928-2934.
- van der Voort E.M.R., Kuipers B., Brugghe H.F., van Unen L.M., Timmermans H.A., Hoogerhout P. and Poolman J.T. (1997). Epitope specificity of murine and human bactericidal antibodies against PorA P1.7, 16 induced with experimental meningococcal group B vaccines. *FEMS Immunol Med Microbiol* **17**, 139-148.
- van Putten J.P. and Robertson B.D. (1995). Molecular mechanisms and implications for infection of lipopolysaccharide variation in *Neisseria*. *Mol Microbiol* **16**, 847-853.
- Vedros N.A. (1987). Development of meningococcal serogroups. In *Evolution of Meningococcal Disease*, Vol 2 CRC Press, Inc., Boca Raton, Fl. p 33-37.
- Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A., *et al.* (2001). The sequence of the human genome. *Science* **291**, 1304-1351.
- Vieusseaux G. (1806). Mémoire sur la maladie qui a régné à Genève au printemps de 1805. *J Med Chi Pharm* **11**, 163-182.
- Virji M. (1996). Meningococcal disease: epidemiology and pathogenesis. *Trends Microbiol* **4**, 466-469.
- Voulhoux R., Bos M.P., Geurtsen J., Mols M. and Tommassen J. (2003). Role of a highly conserved bacterial protein in outer membrane protein assembly. *Science* **299**, 262-265.
- Walhout A.J., Temple G.F., Brasch M.A., Hartley J.L., Lorson M.A., van den Heuvel S. and Vidal M. (2000). GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. *Methods Enzymol* **328**, 575-592.
- Wang L.Y. and Frasch C.E. (1984). Development of a *Neisseria meningitidis* group B serotype 2b protein vaccine and evaluation in a mouse model. *Infect Immun* **46**, 408-414.
- Wang J.F., Caugant D.A., Li X., Hu X., Poolman J.T., Crowe B.A. and Achtman M. (1992). Clonal and antigenic analysis of serogroup A *Neisseria meningitidis* with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. *Infect Immun* **60**, 5267-5282.
- Wang J.F., Caugant D.A., Morelli G., Koumare B. and Achtman M. (1993). Antigenic and epidemiologic properties of the ET-37 complex of *Neisseria meningitidis*. *J Infect Dis* **167**, 1320-1329.

- Wang G., Rasko D.A., Sherburne R. and Taylor D. E. (1999). Molecular genetic basis for the variable expression of Lewis Y antigen in *Helicobacter pylori*: analysis of the alpha (1,2) fucosyltransferase gene. *Mol Microbiol* **31**, 1265-1274.
- Wedeg E. and Froholm L.O. (1986). Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. *Infect Immun* **51**, 571-578.
- Wedeg E., Kuipers B., Bolstad K., van Dijken H., Froholm L.O., Vermont C., Caugant D.A. and van den Dobbelsteen G. (2003). Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. *Infect Immun* **71**, 3775-3781.
- Weekly epidemiological record. Meningococcal Disease. WHO (1999), **36**, 297-303.
- Weekly epidemiological record. Outbreaks News. WHO (2003), **78**, No. 6, 33-40.
- Weiselbaum A. (1887). Ueber die Aetiologie der akuten Meningitis cerebrospinalis. *Fortschr Med* **5**, 573- 583.
- Wells D.B., Tighe P.J., Wooldridge K.G. Robinson K. and Ala'Aldeen D.A. (2001). Differential gene expression during meningeal-meningococcal interaction: evidence for self-defense and early release of cytokines and chemokines. *Infect Immun* **69**, 2718-2722.
- Wildes S.S. and Tunkel A.R. (2002). Meningococcal vaccines: a progress report. *BioDrugs* **16**, 321-329.
- Woods J.P. and Cannon J.G. (1990). Variation in expression of class 1 and class 5 outer membrane proteins during nasopharyngeal carriage of *Neisseria meningitidis*. *Infect Immun* **58**, 569-572.
- Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., Berman S.L. and Lowenthal J.P. (1972). Immunologic response of man to group B meningococcal polysaccharide vaccines. *J Infect Dis* **126**, 514-521.
- Yamaoka Y., Kwon D.H. and Graham D.Y. (2000). A M(r) 34,000 proinflammatory outer membrane protein (*oipA*) of *Helicobacter pylori*. *Proc Natl Acad Sci USA* **97**, 7533-7538.
- Yang Y., Leng Z., Shen X., Lu D., Jiang Z., Rao J., Fan X., Liu J. and Shen Y. (1996). Acute bacterial meningitis in children in Hefei, China 1990-1992. *Chin Med J* **109**, 385-388.
- Zhu H., Bilgin M., Bangham R., Hall D., Casamayor A., Bertone P., Lan N., Jansen R., Bidlingmaier S., Houfek T., Mitchell T., Miller P., Dean R.A., Gerstein M. and Snyder M. (2001). Global analysis of protein activities using proteome chips. *Science* **293**, 2101-2105.

Zollinger W.D., Boslego J., Froholm L.O., Ray J.S., Moran E.E. and Brandt B.L. (1987). Human bactericidal antibody response to meningococcal outer membrane protein vaccines. *Antonie Van Leeuwenhoek* **53**, 403-411.